منابع مشابه
Enzalutamide in prostate cancer after chemotherapy.
To the Editor: In the randomized trial reported by Scher et al. (Sept. 27 issue),1 the administration of enzalutamide, an androgen-receptor–signaling inhibitor, was associated with an increased incidence of headache, as compared with placebo, in patients with castration-resistant prostate cancer. Androgens are implicated in the pathogenesis of migraine; thus, it is important to understand wheth...
متن کاملEnzalutamide in metastatic prostate cancer before chemotherapy.
BACKGROUND Enzalutamide is an oral androgen-receptor inhibitor that prolongs survival in men with metastatic castration-resistant prostate cancer in whom the disease has progressed after chemotherapy. New treatment options are needed for patients with metastatic prostate cancer who have not received chemotherapy, in whom the disease has progressed despite androgen-deprivation therapy. METHODS...
متن کاملAndrogen receptor aberrations and abiraterone/enzalutamide-resistant prostate cancer
Disclosures/Conflicts of Interest: GA has received honoraria, consulting fees or travel support from Astellas, Medivation, Janssen, Millennium Pharmaceuticals, Ipsen, Ventana, Bayer, Essa Pharma, Abbott Labs, Novartis, Veridex and Sanofi-Aventis, and grant support from Janssen, AstraZeneca, Innocrin and Arno. The Institute of Cancer Research developed abiraterone and therefore has a commercial ...
متن کاملTreatment of metastatic castration-resistant prostate cancer (mCRPC) with enzalutamide.
Prostate cancer is initially responsive to androgen deprivation therapy, but most patients eventually develop castration-resistant disease. Enzalutamide is an androgen receptor (AR) inhibitor that targets several steps in the AR signaling pathway and has shown significant efficacy in the treatment of metastatic castration-resistant prostate cancer in patients with or without prior chemotherapy....
متن کاملEnzalutamide for the treatment of metastatic castration-resistant prostate cancer
In recent years, several nonhormonal and hormonal agents, including enzalutamide, have been approved for the treatment of metastatic castration-resistant prostate cancer (CRPC) on the basis of improved overall survival in prospective clinical trials. The incorporation of these agents has revolutionized the treatment of CRPC but has also raised the question of what is the ideal sequence of admin...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Eurasian Journal of Medicine and Oncology
سال: 2018
ISSN: 2587-196X
DOI: 10.14744/ejmo.2018.72098